Independent observational research · GLP-3 is investigational and not FDA-approved
R3TA

Safety

Recording stories, not managing care

R3TA records what participants report. It is not a medical service and cannot advise you. If something feels wrong, contact a qualified clinician — and in an emergency, call your local emergency number.

Commonly reported stories

Gastrointestinal events were the most frequently reported adverse events in the published Phase 2 trial, and increases in heart rate were also observed. The list below reflects what is commonly reported — not what you should expect.

Nausea

The most frequently reported gastrointestinal story in published trial data.

Constipation

Commonly reported, often described as changing over the first weeks.

Diarrhoea

Reported alongside other gastrointestinal stories.

Vomiting

Less frequently reported, but recorded when it occurs.

Reflux

Reported by some participants, often meal-related.

Fatigue

Reported changes in energy across the day.

Seek medical attention right away if you have

  • Chest pain, palpitations, or a persistently fast heart rate
  • Severe or persistent abdominal pain, especially radiating to the back
  • Persistent vomiting or an inability to keep fluids down
  • Signs of dehydration, fainting, or confusion
  • Severe allergic reaction: swelling of the face, lips, or throat, or trouble breathing
  • Any symptom that feels severe, sudden, or frightening

Reporting something to R3TA is never a substitute for contacting a clinician.

How reports are handled

Adverse-experience reports are stored as structured records tied to your private account. They are counted only in de-identified aggregate views and are never published in a way that could identify you.

What we cannot do

We cannot diagnose, advise on dosing, tell you to start or stop anything, or interpret your results for you. GLP-3 is investigational and has not been approved by the FDA.

Read the methodology →